We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| ADC Therapeutics SA | NYSE:ADCT | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.07 | -3.45% | 1.96 | 3,717 | 13:15:18 |
From Jun 2024 to Dec 2024
H.C. Wainwright 26th Annual Global Investment Conference
Date: September 9, 2024Presentation Time: 7:00 a.m. ETFormat: Virtual Fireside Chat Speaker: Ameet Mallik, Chief Executive Officer
10th Cantor Global Healthcare Conference 2024
Date: September 18, 2024 Presentation Time: 11:30-12:00 p.m. ETFormat: Fireside Chat Speaker: Ameet Mallik, Chief Executive Officer
Live webcasts of the presentations will be available via the Events & Presentations page in the Investors section of ADC Therapeutics’ website, ir.adctherapeutics.com. A replay of each webcast will be available for approximately 30 days following each event.
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.
ADC Therapeutics’ CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.
ADC Therapeutics is based in Lausanne (Biopôle), Switzerland, and has operations in London and New Jersey. For more information, please visit the Company website at adctherapeutics.com and follow us on LinkedIn.
ZYNLONTA® is a registered trademark of ADC Therapeutics SA.
CONTACTS:
InvestorsMarcy GrahamADC TherapeuticsMarcy.Graham@adctherapeutics.com+1 650-667-6450
MediaNicole RileyADC TherapeuticsNicole.Riley@adctherapeutics.com+1 862-926-9040
1 Year ADC Therapeutics Chart |
1 Month ADC Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
